Karin Kozbial1, Stephan Moser2, Ramona Al-Zoairy3, Remy Schwarzer4, Christian Datz5, Rudolf Stauber6, Hermann Laferl7, Michael Strasser8, Sandra Beinhardt1, Albert F Stättermayer1, Michael Gschwantler2, Heinz Zoller3, Andreas Maieron4,9, Ivo Graziadei10, Michael Trauner1, Petra Steindl-Munda1, Harald Hofer1,11, Peter Ferenci1. 1. Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria. 2. Department of Internal Medicine IV, Wilhelminenspital, Vienna, Austria. 3. Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria. 4. Department of Internal Medicine IV, Ordensklinikum Linz, Elisabethinen, Linz, Austria. 5. Department of Internal Medicine, Krankenhaus Oberndorf, Teaching hospital of the Paracelsus Private Medical University of Salzburg, Oberndorf, Austria. 6. Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria. 7. Department of Internal Medicine, Kaiser-Franz-Josef-Spital, Vienna, Austria. 8. Department of Internal Medicine I, Paracelsus University of Salzburg, Salzburg, Austria. 9. Department of Internal Medicine II, University Clinics St. Pölten, St. Pölten, Austria. 10. Department of Internal Medicine, Landeskrankenhaus Hall, Tirol, Austria. 11. Department of Internal Medicine I, Klinikum Wels-Grieskirchen, Wels, Austria.
Abstract
BACKGROUND: The introduction of direct-acting antivirals (DAA) has increased sustained virological response (SVR) rates in patients with advanced liver disease and chronic hepatitis C(CHC)infection. At present, data on clinical outcome and long-term durability of viral eradication after successful DAA therapy are scarce. AIM: To evaluate the long-term success of viral eradication in patients with advanced fibrosis or cirrhosis treated with DAAs. METHODS: Five hundred and fifty-one patients with advanced fibrosis (n = 158) or cirrhosis (CPS-A:317,CPS-B/C:76) and SVR after interferon and ribavirin-free DAA therapy treated between October 2013 and April 2016 were studied with a median follow-up of 65.6 (13.0-155.3) weeks. Only patients without hepatocellular carcinoma (HCC) at baseline and without liver transplantation were included. RESULTS: Twelve patients (2.2%) died during follow-up: the mortality rate was 0.6% in F3, 2.2% in CPS-A and 5.3% in CPS-B/C patients (P = .08). During follow-up 36 patients with cirrhosis (9.1%) developed a liver related event, including 16 with de-novo HCC (4.1%). Seven patients were transplanted at a median of 9.7 (range 3.8-21.7) months after EOT. History of decompensation was significantly associated with liver related events during follow-up (HR 7.9; 95% CI 2.7-22.6; P < .001), and with mortality (HR 5.5; 95% CI 1.5-20.2, P = .01). CONCLUSIONS: Eradication of HCV by DAA therapy was durable irrespective of the DAA combination used. Most of the cured patients had an excellent long-term clinical prognosis. Nevertheless, the risk of new occurrence of HCC remains worrisome and thus regular surveillance is obligatory even after clinical stabilization and improvement of the patient.
BACKGROUND: The introduction of direct-acting antivirals (DAA) has increased sustained virological response (SVR) rates in patients with advanced liver disease and chronic hepatitis C(CHC)infection. At present, data on clinical outcome and long-term durability of viral eradication after successful DAA therapy are scarce. AIM: To evaluate the long-term success of viral eradication in patients with advanced fibrosis or cirrhosis treated with DAAs. METHODS: Five hundred and fifty-one patients with advanced fibrosis (n = 158) or cirrhosis (CPS-A:317,CPS-B/C:76) and SVR after interferon and ribavirin-free DAA therapy treated between October 2013 and April 2016 were studied with a median follow-up of 65.6 (13.0-155.3) weeks. Only patients without hepatocellular carcinoma (HCC) at baseline and without liver transplantation were included. RESULTS: Twelve patients (2.2%) died during follow-up: the mortality rate was 0.6% in F3, 2.2% in CPS-A and 5.3% in CPS-B/C patients (P = .08). During follow-up 36 patients with cirrhosis (9.1%) developed a liver related event, including 16 with de-novo HCC (4.1%). Seven patients were transplanted at a median of 9.7 (range 3.8-21.7) months after EOT. History of decompensation was significantly associated with liver related events during follow-up (HR 7.9; 95% CI 2.7-22.6; P < .001), and with mortality (HR 5.5; 95% CI 1.5-20.2, P = .01). CONCLUSIONS: Eradication of HCV by DAA therapy was durable irrespective of the DAA combination used. Most of the cured patients had an excellent long-term clinical prognosis. Nevertheless, the risk of new occurrence of HCC remains worrisome and thus regular surveillance is obligatory even after clinical stabilization and improvement of the patient.
Authors: Ekram W Abd El-Wahab; Waleed M Abd Elgawad; Mohamed S Abdelaziz; Ashraf I Mikheal; Hanan Z Shatat Journal: Am J Trop Med Hyg Date: 2022-02-28 Impact factor: 3.707
Authors: Tea L Laursen; Thomas D Sandahl; Konstantin Kazankov; Jacob George; Henning Grønbæk Journal: World J Gastroenterol Date: 2020-06-14 Impact factor: 5.742
Authors: Ewa Janczewska; Dorota Zarębska-Michaluk; Hanna Berak; Anna Piekarska; Andrzej Gietka; Dorota Dybowska; Włodzimierz Mazur; Teresa Belica-Wdowik; Witold Dobracki; Magdalena Tudrujek-Zdunek; Zbigniew Deroń; Iwona Buczyńska; Marek Sitko; Agnieszka Czauż-Andrzejuk; Beata Lorenc; Jolanta Białkowska-Warzecha; Jolanta Citko; Łukasz Laurans; Jerzy Jaroszewicz; Łukasz Socha; Olga Tronina; Brygida Adamek; Andrzej Horban; Waldemar Halota; Barbara Baka-Ćwierz; Krzysztof Tomasiewicz; Krzysztof Simon; Aleksander Garlicki; Marta Wawrzynowicz-Syczewska; Robert Flisiak Journal: BMC Infect Dis Date: 2018-11-16 Impact factor: 3.090
Authors: Eric Lawitz; Fred Poordad; Julio A Gutierrez; Maria Beumont; Greet Beets; Ann Vandevoorde; Pieter Van Remoortere; Donghan Luo; Leen Vijgen; Veerle Van Eygen; Mohamed Gamil Journal: Health Sci Rep Date: 2020-02-22